171 related articles for article (PubMed ID: 34923338)
1. An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry.
Hruba L; Polishchuk P; Das V; Hajduch M; Dzubak P
Biomed Pharmacother; 2022 Feb; 146():112549. PubMed ID: 34923338
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pyrazolopyrimidine derivatives as microtubule affinity regulating kinase 4 inhibitors: Towards therapeutic management of Alzheimer's disease.
Naqvi AAT; Jairajpuri DS; Noman OMA; Hussain A; Islam A; Ahmad F; Alajmi MF; Hassan MI
J Biomol Struct Dyn; 2020 Aug; 38(13):3892-3907. PubMed ID: 31512980
[TBL] [Abstract][Full Text] [Related]
3. Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease.
Gu GJ; Lund H; Wu D; Blokzijl A; Classon C; von Euler G; Landegren U; Sunnemark D; Kamali-Moghaddam M
Neuromolecular Med; 2013 Sep; 15(3):458-69. PubMed ID: 23666762
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Microtubule Affinity Regulating Kinase 4 by Metformin: Exploring the Neuroprotective Potential of Antidiabetic Drug through Spectroscopic and Computational Approaches.
Ashraf GM; DasGupta D; Alam MZ; Baeesa SS; Alghamdi BS; Anwar F; Alqurashi TMA; Sharaf SE; Al Abdulmonem W; Alyousef MA; Alhumaydhi FA; Shamsi A
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889524
[TBL] [Abstract][Full Text] [Related]
5. Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.
Annadurai N; Agrawal K; Džubák P; Hajdúch M; Das V
Cell Mol Life Sci; 2017 Nov; 74(22):4159-4169. PubMed ID: 28634681
[TBL] [Abstract][Full Text] [Related]
6. Microtubule affinity-regulating kinase 4 with an Alzheimer's disease-related mutation promotes tau accumulation and exacerbates neurodegeneration.
Oba T; Saito T; Asada A; Shimizu S; Iijima KM; Ando K
J Biol Chem; 2020 Dec; 295(50):17138-17147. PubMed ID: 33020179
[TBL] [Abstract][Full Text] [Related]
7. Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262.
Saito T; Oba T; Shimizu S; Asada A; Iijima KM; Ando K
Hum Mol Genet; 2019 Sep; 28(18):3062-3071. PubMed ID: 31174206
[TBL] [Abstract][Full Text] [Related]
8. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
9. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes.
Trinczek B; Brajenovic M; Ebneth A; Drewes G
J Biol Chem; 2004 Feb; 279(7):5915-23. PubMed ID: 14594945
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.
Sun W; Lee S; Huang X; Liu S; Inayathullah M; Kim KM; Tang H; Ashford JW; Rajadas J
Sci Rep; 2016 Oct; 6():34784. PubMed ID: 27708431
[TBL] [Abstract][Full Text] [Related]
11. MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies.
Lund H; Gustafsson E; Svensson A; Nilsson M; Berg M; Sunnemark D; von Euler G
Acta Neuropathol Commun; 2014 Feb; 2():22. PubMed ID: 24533944
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.
Schneider A; Biernat J; von Bergen M; Mandelkow E; Mandelkow EM
Biochemistry; 1999 Mar; 38(12):3549-58. PubMed ID: 10090741
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.
Lund ET; McKenna R; Evans DB; Sharma SK; Mathews WR
J Neurochem; 2001 Feb; 76(4):1221-32. PubMed ID: 11181841
[TBL] [Abstract][Full Text] [Related]
14. Targeting inhibition of microtubule affinity regulating kinase 4 by Harmaline: Strategy to combat Alzheimer's disease.
Adnan M; Anwar S; DasGupta D; Patel M; Elasbali AM; Alhassan HH; Shafie A; Siddiqui AJ; Bardakci F; Snoussi M; Hassan MI
Int J Biol Macromol; 2023 Jan; 224():188-195. PubMed ID: 36257368
[TBL] [Abstract][Full Text] [Related]
15. A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.
Yu W; Polepalli J; Wagh D; Rajadas J; Malenka R; Lu B
Hum Mol Genet; 2012 Mar; 21(6):1384-90. PubMed ID: 22156579
[TBL] [Abstract][Full Text] [Related]
16. Microtubule-affinity regulating kinase family members distinctively affect tau phosphorylation and promote its toxicity in a Drosophila model.
Sultanakhmetov G; Kato I; Asada A; Saito T; Ando K
Genes Cells; 2024 Apr; 29(4):337-346. PubMed ID: 38329182
[TBL] [Abstract][Full Text] [Related]
17. Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease.
Gu GJ; Wu D; Lund H; Sunnemark D; Kvist AJ; Milner R; Eckersley S; Nilsson LN; Agerman K; Landegren U; Kamali-Moghaddam M
J Alzheimers Dis; 2013; 33(3):699-713. PubMed ID: 23001711
[TBL] [Abstract][Full Text] [Related]
18. MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer's Disease.
Waseem R; Anwar S; Khan S; Shamsi A; Hassan MI; Anjum F; Shafie A; Islam A; Yadav DK
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681645
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of microtubule affinity regulating kinase 4 by an acetylcholinesterase inhibitor, Huperzine A: Computational and experimental approaches.
Alrouji M; DasGupta D; Ashraf GM; Bilgrami AL; Alhumaydhi FA; Al Abdulmonem W; Shahwan M; Alsayari A; Atiya A; Shamsi A
Int J Biol Macromol; 2023 Apr; 235():123831. PubMed ID: 36870649
[TBL] [Abstract][Full Text] [Related]
20. The microtubule-associated protein tau is also phosphorylated on tyrosine.
Lebouvier T; Scales TM; Williamson R; Noble W; Duyckaerts C; Hanger DP; Reynolds CH; Anderton BH; Derkinderen P
J Alzheimers Dis; 2009; 18(1):1-9. PubMed ID: 19542604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
